Bio-Techne Stock Surges 37% as Institutional Investors Reshape Holdings
Bio-Techne Corp shares have surged approximately 37% over the past month as institutional investors adjust their holdings in the Minnesota-based life sciences company. The company surpassed quarterly revenue expectations with $295.88 million, while recently divesting Exosome Diagnostics to focus on higher-margin core segments.
Bio-Techne Corp (TECH) shares have surged approximately 37% over the past month, reaching a latest share price of $71.0 after recording a 22.5% return over the past seven days and 37.4% over 30 days. Despite this recent momentum, the stock's 5-year total shareholder return remains down 35.4%, raising questions about whether current valuations are sustainable.
The Minnesota-based life sciences manufacturer, which supplies consumables and instruments for pharmaceutical, biotech, academic, and diagnostic markets, reported quarterly earnings on February 4th with earnings per share of $0.46, revenue of $295.88 million (surpassing analyst expectations of $290.19 million), a return on equity of 4.06%, and a net margin of 6.67%.
Institutional investors have been actively adjusting their positions in the stock. Global X Genomics & Biotechnology ETF reduced its stake by 1.02%, selling 341 shares to hold 33,104 shares valued at approximately $2.14 million. Meanwhile, several other funds increased their holdings: Avantis U.S. Equity ETF raised its stake by 16.1% with the purchase of 1,169 shares, Column Small Cap Select Fund increased its position by 62.75% by acquiring 12,152 shares, and Column Small Cap Fund grew its stake by 45.47% by adding 1,539 shares.
The company recently divested Exosome Diagnostics, allowing redeployment of capital toward higher-margin core business segments. Management expects this shift to support 100 to 200 basis points of operating margin expansion. Bio-Techne operates in two segments: protein sciences (approximately 75% of revenue) and diagnostics and genomics (25%), with the United States accounting for about 55% of revenue.
Stock performance data shows Bio-Techne trading with a 52-week range of $46.01 to $72.16, a debt-to-equity ratio of 0.17, and a market capitalization of approximately $8.37 billion to $9.38 billion. The company maintains a quick ratio of 3.08 and current ratio of 4.54.
However, the stock's forward outlook faces potential headwinds from weak biotech funding and geopolitical and regulatory uncertainties that could weigh on customer spending and margins.